The answer will probably come from future refinements and the widespread adoption of PSMA-PET, which has proven to be superior to conventional imaging for high-risk PCa patients with pelvic nodal metastases [25,26,27,28,29]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.